Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.

Pei J, Cooper H, Flieder DB, Talarchek JN, Al-Saleem T, Uzzo RG, Dulaimi E, Patchefsky AS, Testa JR, Wei S.

Mod Pathol. 2019 Jan 8. doi: 10.1038/s41379-018-0191-7. [Epub ahead of print]

PMID:
30622287
2.

Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.

Kadariya Y, Menges CW, Talarchek J, Cai KQ, Klein-Szanto AJ, Pietrofesa RA, Christofidou-Solomidou M, Cheung M, Mossman BT, Shukla A, Testa JR.

Cancer Prev Res (Phila). 2016 May;9(5):406-414. doi: 10.1158/1940-6207.CAPR-15-0347. Epub 2016 Mar 2.

3.

Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.

Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR.

Cancer Res. 2016 Jan 15;76(2):206-15. doi: 10.1158/0008-5472.CAN-15-0295. Epub 2015 Dec 30. Erratum in: Cancer Res. 2018 Jan 1;78(1):309. Cancer Res. 2017 Jun 1;77(11):3124.

4.

Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.

Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, Testa JR.

Cancer Lett. 2015 Dec 28;369(2):261-5. doi: 10.1016/j.canlet.2015.09.011. Epub 2015 Sep 26.

5.

An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.

Cheung M, Kadariya Y, Pei J, Talarchek J, Facciolo F, Visca P, Righi L, Cozzi I, Testa JR, Ascoli V.

Cancer Genet. 2015 Oct;208(10):502-7. doi: 10.1016/j.cancergen.2015.07.004. Epub 2015 Jul 30.

6.

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.

Kalra N, Zhang J, Thomas A, Xi L, Cheung M, Talarchek J, Burkett S, Tsokos MG, Chen Y, Raffeld M, Miettinen M, Pastan I, Testa JR, Hassan R.

BMC Cancer. 2015 May 8;15:376. doi: 10.1186/s12885-015-1362-2.

7.

Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.

Albury TM, Pandey V, Gitto SB, Dominguez L, Spinel LP, Talarchek J, Klein-Szanto AJ, Testa JR, Altomare DA.

Neoplasia. 2015 Feb;17(2):175-82. doi: 10.1016/j.neo.2014.12.006.

8.

Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, Karar J, Rauscher FJ, Testa JR.

Cancer Res. 2014 Aug 15;74(16):4388-97. doi: 10.1158/0008-5472.CAN-14-1328. Epub 2014 Jun 13.

9.

Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pei J, Robu V, Feder M, Cheung M, Neumann-Domer E, Talarchek J, Dulaimi E, Millenson MM, Testa JR.

Cancer Genet. 2014 Mar;207(3):98-102. doi: 10.1016/j.cancergen.2014.02.005. Epub 2014 Feb 15.

10.

Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.

Menges CW, Kadariya Y, Altomare D, Talarchek J, Neumann-Domer E, Wu Y, Xiao GH, Shapiro IM, Kolev VN, Pachter JA, Klein-Szanto AJ, Testa JR.

Cancer Res. 2014 Feb 15;74(4):1261-1271. doi: 10.1158/0008-5472.CAN-13-2062. Epub 2013 Dec 26.

11.

Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.

Cheung M, Talarchek J, Schindeler K, Saraiva E, Penney LS, Ludman M, Testa JR.

Cancer Genet. 2013 May;206(5):206-10. doi: 10.1016/j.cancergen.2013.05.018. Review.

PMID:
23849051
12.

Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.

Menges CW, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson JR, Testa JR.

Mol Cancer Res. 2012 Sep;10(9):1178-88. Epub 2012 Jul 12.

Supplemental Content

Loading ...
Support Center